Work

Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2514

Authors: Jung-min Lee, Christina M. Annunziata, John L. Hays, Anne M. Noonan, Lori M. Minasian, JoAnne Zujewski, Minshu Yu, Jiuping Jay Ji, Tristan Sissung, Nicole D. Houston, Elise C. Kohn

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Science Applications International Corporation (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2744490258

Cites:

Cited by: 9

Related to: 10